Cardiff Oncology, Inc. Common Stock (CRDF) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDF trades at $1.84 with a market cap of $115.55M and a P/E ratio of -1.95. CRDF moved +4.55% today. Year to date, CRDF is -35.21%; over the trailing twelve months it is -40.07%. Its 52-week range spans $1.48 to $5.64. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces CRDF's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cardiff Oncology Posts 72.2% ORR in Phase 2, Secures 30 mg Onvansertib Dose for Phase 3: Cardiff completed an End-of-Phase 2 FDA meeting and selected a 30 mg onvansertib plus FOLFIRI/bevacizumab regimen for its registrational Phase 3 trial in first-line RAS-mutated mCRC. Phase 2 trial showed 72.2% response versus 43.2% standard care and 0.38 PFS HR, while $46.1M cash funds through Q1 2027.
| Metric | Value |
|---|---|
| Price | $1.84 |
| Market Cap | $115.55M |
| P/E Ratio | -1.95 |
| EPS | $-0.93 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.64 |
| 52-Week Low | $1.48 |
| Volume | 23 |
| Avg Volume | 0 |
| Revenue (TTM) | $488.00K |
| Net Income | $-41.44M |
| Gross Margin | 0.00% |
6 analysts cover CRDF: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.33.